Výsledky vyhledávání - "Brigham Hyde"

Akademický článek

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease

Autor: David Andrew Bender, Samuel P Heilbroner, Tony J C Wang, Catherine A Shu, Brigham Hyde, Catherine Spina, Simon K Cheng

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background Immune checkpoint inhibitors (ICIs) are important new therapeutic options for the treatment of malignancy. Existing data on the relative safety of ICI treatment in patients with pre-existing autoimmune disease (AID) are limited.Methods In

Externí odkaz: https://doaj.org/article/f082b00aaab142aebb00fde419df7353

Zobrazit plný text záznamu

Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer

Autor: Chin Hur, Brigham Hyde, Adam S. Faye, David Andrew Bender, Simon K. Cheng, Lawrence Koutcher, Kate E Lee

Publikováno v: Cancer. 128:819-827

BACKGROUND Immune checkpoint inhibitors (ICIs) are potent new cancer therapies but can cause serious immune-related adverse events. ICIs have contributed significantly to improved survival and thereby provide more opportunity for the development of l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::096c5e74953e0d30d61237f83183e55e
https://doi.org/10.1002/cncr.33975

Zobrazit plný text záznamu

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease

Autor: Samuel P. Heilbroner, David Andrew Bender, Brigham Hyde, Simon K. Cheng, Catherine S. Spina, Catherine A. Shu, Tony J. C. Wang

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

BackgroundImmune checkpoint inhibitors (ICIs) are important new therapeutic options for the treatment of malignancy. Existing data on the relative safety of ICI treatment in patients with pre-existing autoimmune disease (AID) are limited.MethodsIn th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::777549900148a87addf1602b0aa170e3
http://europepmc.org/articles/PMC7733208

Zobrazit plný text záznamu

Risk of immunosuppression and hospitalization after checkpoint inhibitor therapy in patients with cancer and radiation therapy

Autor: Kate E Lee, David Andrew Bender, Adam S. Faye, Simon K. Cheng, Catherine S. Spina, Brigham Hyde

Publikováno v: Journal of Clinical Oncology. 39:2588-2588

2588 Background: Immune checkpoint inhibitors (ICIs) are potent new cancer therapies but can cause serious immune-related adverse events. Radiation therapy (RT) also induces systemic immunologic effects, and data on the interaction and safety of comb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::daae285904f4f7ba23ea627114a79b76
https://doi.org/10.1200/jco.2021.39.15_suppl.2588

Zobrazit plný text záznamu

Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis

Autor: Suanna S. Bruinooge, Elizabeth Garrett-Mayer, Li Chen, Wendy S. Rubinstein, George Anthony Komatsoulis, Brigham Hyde, R. Donald Harvey, Caroline Schenkel, Sean Khozin, Edward S. Kim, Edward J. Stepanski, Monika Jun, Thomas S. Uldrick, Gwynn Ison, Jeremy Roberts, Richard L. Schilsky, Robert S. Miller

Publikováno v: Journal of Clinical Oncology. 37:LBA108-LBA108

LBA108 Background: Restrictive trial eligibility criteria limit data generalizability and patient opportunity to participate. We compared numbers and characteristics of patients (pts) eligible using traditional vs expanded criteria recommended by ASC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e61f15919b80d7e431fb7eb5d8ac74a
https://doi.org/10.1200/jco.2019.37.18_suppl.lba108

Zobrazit plný text záznamu

Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor

Autor: George Anthony Komatsoulis, Sean Khozin, Li Chen, Ryan Fukushima, Edward J. Stepanski, Mark S. Walker, Jeremy Roberts, Monika Jun, Robert S. Miller, Jizu Zhi, Brigham Hyde, Wendy S. Rubinstein, Denise Lau

Publikováno v: Journal of Clinical Oncology. 37:9110-9110

9110 Background: Immune Checkpoint Inhibitors (ICIs) were first approved for the treatment of aNSCLC in 2014, and since this time have seen rapid adoption in the marketplace. We sought to describe the characteristics of patients with aNSCLC receiving

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1225bb235c0311d8adb98e1ce295dac
https://doi.org/10.1200/jco.2019.37.15_suppl.9110

Zobrazit plný text záznamu

Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs)

Autor: Robert S. Miller, Edward J. Stepanski, Mark S. Walker, Sean Khozin, Monika Jun, Ryan Fukushima, Jizu Zhi, Jeremy Roberts, Brigham Hyde, Wendy S. Rubinstein, Li Chen, George Anthony Komatsoulis, Denise Lau

Publikováno v: Journal of Clinical Oncology. 37:110-110

110 Background: Anecdotal and early evidence suggest ICIs are being used in patients with advanced malignancies and history of AD, despite such patients being typically excluded from traditional clinical trials. We compared the outcomes of patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd33638c242b6163c3463fe1e1e24036
https://doi.org/10.1200/jco.2019.37.15_suppl.110

Zobrazit plný text záznamu

Rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in melanoma and lung cancer patients with autoimmune diseases

Autor: Brigham Hyde, David Andrew Bender, Paul Reuscher, Eric Xanthopoulos, Samuel P. Heilbroner, Catherine S. Spina, Simon K. Cheng, Tony J. C. Wang

Publikováno v: Journal of Clinical Oncology. 37:e14140-e14140

e14140 Background: Immune checkpoint inhibitors (ICIs) are known to cause immune-related adverse events. Patients with autoimmune diseases (AID) were excluded from most ICI clinical trials due to the potentially high risk of adverse effects. Data on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74af7bdc91dcc641656272b3ff29b294
https://doi.org/10.1200/jco.2019.37.15_suppl.e14140

Zobrazit plný text záznamu

Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients

Autor: Babu Narayanan, Hemant Kulkarni, Karl Rudeen, Prajwal Chandrashekaraiah, Orr Inbar, Vivek Prabhakar Vaidya, Li Chen, Brigham Hyde, Smita Agrawal

Publikováno v: Journal of Clinical Oncology. 37:6556-6556

6556 Background: Survival prediction models for lung cancer patients could help guide their care and therapy decisions. The objectives of this study were to predict probability of survival beyond 90, 180 and 360 days from any point in a lung cancer p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43894751ffb4023653d64e9cec915011
https://doi.org/10.1200/jco.2019.37.15_suppl.6556

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání